Charles Schwab Investment Management Inc Arbutus Biopharma Corp Transaction History

Charles Schwab Investment Management Inc

$527 Billion
Q4 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,222,201 shares of ABUS stock, worth $3.91 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,222,201

Previous 1,212,246 0.82%

Holding current value

$3.91 Million

Previous $4.67 Million 14.38%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 06, 2025	BUY	$3.18 - $4.2 $31,656 - $41,811	9,955 Added 0.82%	1,222,201 $4 Million
Q3 2024 Nov 12, 2024	BUY	$3.12 - $4.56 $2.59 Million - $3.79 Million	831,663 Added 218.52%	1,212,246 $4.67 Million
Q2 2024 Aug 12, 2024	BUY	$2.52 - $3.63 $104,247 - $150,165	41,368 Added 12.2%	380,583 $1.18 Million
Q1 2024 May 08, 2024	SELL	$2.26 - $2.92 $22,923 - $29,617	-10,143 Reduced 2.9%	339,215 $875,000
Q3 2023 Nov 08, 2023	BUY	$1.9 - $2.27 $25,241 - $30,156	13,285 Added 3.95%	349,358 $709,000
Q2 2023 Aug 09, 2023	BUY	$2.24 - $3.06 $60,712 - $82,938	27,104 Added 8.77%	336,073 $772,000
Q1 2023 May 11, 2023	BUY	$2.23 - $3.1 $8,226 - $11,435	3,689 Added 1.21%	308,969 $936,000
Q4 2022 Feb 13, 2023	BUY	$1.91 - $2.85 $34,114 - $50,903	17,861 Added 6.21%	305,280 $711,000
Q3 2022 Nov 14, 2022	SELL	$1.88 - $2.88 $1,005 - $1,540	-535 Reduced 0.19%	287,419 $549,000
Q2 2022 Aug 15, 2022	BUY	$1.98 - $3.17 $95,517 - $152,923	48,241 Added 20.12%	287,954 $781,000
Q1 2022 May 13, 2022	BUY	$2.42 - $3.98 $73,417 - $120,745	30,338 Added 14.49%	239,713 $715,000
Q3 2021 Nov 16, 2021	BUY	$2.65 - $4.62 $60,703 - $105,830	22,907 Added 12.28%	209,375 $899,000
Q2 2021 Aug 16, 2021	BUY	$2.5 - $3.51 $413,890 - $581,101	165,556 Added 791.68%	186,468 $565,000
Q4 2020 Feb 16, 2021	SELL	$2.76 - $4.97 $33,120 - $59,640	-12,000 Reduced 36.46%	20,912 $75,000
Q3 2020 Nov 13, 2020	BUY	$1.75 - $6.2 $57,596 - $204,054	32,912 New	32,912 $104,000
Q2 2019 Aug 09, 2019	SELL	$1.46 - $4.44 $96,214 - $292,596	-65,900 Closed	0 $0
Q2 2018 Aug 08, 2018	BUY	$5.0 - $7.35 $329,500 - $484,365	65,900 New	65,900 $482,000

Others Institutions Holding ABUS

# of Institutions

165

Shares Held

102M

Call Options Held

649K

Put Options Held

666K

View Full List

About Arbutus Biopharma Corp

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $480M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

More about ABUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Arbutus Biopharma Corp Transaction History